Adjunctive Surgery Is Often Without Oncological Benefit at Time of Postchemotherapy Retroperitoneal Lymph Node Dissection

被引:3
作者
Nestler, Tim [1 ,2 ,6 ]
Paffenholz, Pia [1 ]
Pfister, David [1 ]
Schoch, Justine [2 ]
Nini, Alessandro [3 ]
Hiester, Andreas [4 ]
Albers, Peter [4 ]
Heidenreich, Axel [1 ,5 ]
机构
[1] Univ Hosp Cologne, Dept Urol & Uro Oncol, Cologne, Germany
[2] Fed Armed Serv Hosp Koblenz, Dept Urol, Koblenz, Germany
[3] Azienda ULSS 7 Pedemontana, Dept Urol, Bassano Del Grappa, Italy
[4] Heinrich Heine Univ Duesseldorf, Dept Urol, Dusseldorf, Germany
[5] Med Univ, Dept Urol, Vienna, Austria
[6] Univ Hosp Cologne, Dept Urol, Uro Oncol, Robot Assisted & Reconstruct Urol Surg, Kerpener Str 62, D-50937 Cologne, Germany
关键词
germ cell cancer; platinum-based chemotherapy; testicular cancer; adjunctive surgery; overtreatment; GERM-CELL TUMORS; TESTICULAR CANCER; CLASSIFICATION; COMPLICATIONS; MANAGEMENT; RESECTION; BENIGN; MASSES; MEN;
D O I
10.1097/JU.0000000000003812
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose:Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for advanced nonseminomatous germ cell tumors (GCTs) aims to resect all remaining metastatic tissue. Resection of adjacent visceral or vascular organs is commonly performed for complete resection. Resection of organs harboring only necrosis results in relevant overtreatment. The study aimed to describe the frequency of metastatic involvement of resected organs with teratoma or viable cancer and to analyze perioperative complications and relapse-free survival. Materials and Methods:In a 2-center study, we reviewed a cohort of 1204 patients who underwent PC-RPLND between 2008 and 2021 and identified 242 (20%) cases of adjunctive surgery during PC-RPLND. We analyzed the removed adjacent structures and the pathohistological presence of GCT elements in the resected organs: viable GCT, teratoma, or necrosis/fibrosis. Surgery-associated complications were reported according to the Clavien-Dindo classification. Results:Viable GCT, teratoma, and necrosis were present in 54 (22%), 94 (39%), and 94 (39%), respectively, of all patients with adjunctive resection of adjacent organs. Vascular resections or reconstructions (n = 112; viable: 23%, teratoma: 41%, necrosis: 36%) were performed most frequently, followed by nephrectomies (n = 77; viable: 29%, teratoma: 39%, necrosis: 33%). Perioperative complications of grade >= IIIa occurred in 6.6% of all patients, with no difference between the viable GCT and teratoma/necrosis groups (P = .1). A total of 76 patients have been followed without a relapse for at least 36 months. Median follow-up of the whole cohort was 22 months (quartile 7 and 48). Patients with viable GCT/teratoma in the resected specimens had a significantly increased risk of recurrence by 5 years compared to patients with only necrosis (19% vs 59% vs 81%, P < .001). Conclusions:This study shows that 33% to 40% of all resections of adjacent organs do not harbor teratoma or viable GCT. This highlights the need for better patient selection for these complex patients.
引用
收藏
页码:426 / 435
页数:9
相关论文
共 32 条
[1]   Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer [J].
Antonelli, Luca ;
Ardizzone, Davide ;
Tachibana, Isamu ;
Adra, Nabil ;
Cary, Clint ;
Hugar, Lee ;
Sexton, Wade J. ;
Bagrodia, Aditya ;
Mego, Michal ;
Daneshmand, Siamak ;
Nicolai, Nicola ;
Nazzani, Sebastiano ;
Giannatempo, Patrizia ;
Franza, Andrea ;
Heidenreich, Axel ;
Paffenholz, Pia ;
Saoud, Ragheed ;
Eggener, Scott ;
Ho, Matthew ;
Oswald, Nathaniel ;
Olson, Kathleen ;
Tryakin, Alexey ;
Fedyanin, Mikhail ;
Naoun, Natacha ;
Javaud, Christophe ;
Cazzaniga, Walter ;
Nicol, David ;
Gerdtsson, Axel ;
Tandstad, Torgrim ;
Fizazi, Karim ;
Fankhauser, Christian Daniel .
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (34) :5296-+
[2]   Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection [J].
Baessler, Bettina ;
Nestler, Tim ;
dos Santos, Daniel ;
Paffenholz, Pia ;
Zeuch, Vikram ;
Pfister, David ;
Maintz, David ;
Heidenreich, Axel .
EUROPEAN RADIOLOGY, 2020, 30 (04) :2334-2345
[3]   Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer [J].
Beck, Stephen D. W. ;
Foster, Richard S. .
WORLD JOURNAL OF UROLOGY, 2006, 24 (03) :267-272
[4]   Additional surgical procedures and perioperative morbidity in post-chemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer in two intermediate volume hospitals [J].
Blok, Joost M. ;
Meijer, Richard P. ;
van der Poel, Henk G. ;
Bex, Axel ;
van Vooren, Jeanette ;
van Urk, Japke J. ;
Horenblas, Simon ;
Bosch, J. L. H. Ruud .
WORLD JOURNAL OF UROLOGY, 2021, 39 (03) :839-846
[5]   Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors [J].
Carver, Brett S. ;
Serio, Angel M. ;
Bajorin, Dean ;
Motzer, Robert J. ;
Stasi, Jason ;
Bosl, George J. ;
Vickers, Andrew J. ;
Sheinfeld, Joel .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (35) :5603-5608
[6]   Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma [J].
Carver, Brett S. ;
Shayegan, Bobby ;
Serio, Angel ;
Motzer, Robert J. ;
Bosl, George J. ;
Sheinfeld, Joel .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) :1033-1037
[7]   Contemporary trends in postchemotherapy retroperitoneal lymph node dissection: Additional procedures and perioperative complications [J].
Cary, Clint ;
Masterson, Timothy A. ;
Bihrle, Richard ;
Foster, Richard S. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (09) :389.e15-389.e21
[8]   Clinical and Pathological Features Predictive of Nephrectomy at Post-Chemotherapy Retroperitoneal Lymph Node Dissection [J].
Cary, K. Clint ;
Beck, Stephen D. W. ;
Bihrle, Richard ;
Foster, Richard S. .
JOURNAL OF UROLOGY, 2013, 189 (03) :812-817
[9]   Contemporary Management of Postchemotherapy Testis Cancer [J].
Daneshmand, Siamak ;
Albers, Peter ;
Fossa, Sophie Dorothea ;
Heidenreich, Axel ;
Kollmannsberger, Christian ;
Krege, Susan ;
Nichols, Craig ;
Oldenburg, Jan ;
Wood, Lori .
EUROPEAN UROLOGY, 2012, 62 (05) :867-876
[10]   False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma [J].
Decoene, Jasper ;
Winter, Christian ;
Albers, Peter .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (01) :23.e15-23.e21